Argenica Therapeutics Ltd
AGN
Company Profile
Business description
Argenica Therapeutics Ltd is engaged in the development and commercialization of novel drug candidates. Its ARG007 drug improves outcomes in pre-clinical stroke models and is in the process of being verified for its safety and toxicology before commencing Phase 1 clinical trials in humans.
Contact
117 Broadway
Unit 4
NedlandsWA6009
AUST: +61 893293396
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,360.40 | 13.60 | -0.16% |
| CAC 40 | 7,727.93 | 42.55 | -0.55% |
| DAX 40 | 23,344.54 | 257.89 | 1.12% |
| Dow JONES (US) | 41,218.83 | 98.60 | -0.24% |
| FTSE 100 | 8,596.35 | 99.55 | 1.17% |
| HKSE | 22,599.13 | 94.45 | 0.42% |
| NASDAQ | 17,844.24 | 133.49 | -0.74% |
| Nikkei 225 | 36,830.69 | 378.39 | 1.04% |
| NZX 50 Index | 12,415.38 | 5.87 | -0.05% |
| S&P 500 | 5,650.38 | 36.29 | -0.64% |
| S&P/ASX 200 | 8,142.90 | 14.90 | -0.18% |
| SSE Composite Index | 3,297.68 | 18.65 | 0.57% |